{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:59Z","timestamp":1790916839685,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":153,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["NCC202404003"],"award-info":[{"award-number":["NCC202404003"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["2023ZD0502100"],"award-info":[{"award-number":["2023ZD0502100"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101275","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:35:57Z","timestamp":1780724157000},"page":"101275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical efficacy and safety of an overall strategy of immunotherapy combined with chemoradiotherapy for limited-stage small cell lung cancer (including induction \u00b1 consolidation \u00b1 second-line immunotherapy): A propensity score matching study based on real-world data"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9060-3178","authenticated-orcid":false,"given":"Anqi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baixue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101275_bib0001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","article-title":"SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection","volume":"18","author":"Wang","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101275_bib0002","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41571-019-0316-z","article-title":"Immunotherapeutic approaches for small-cell lung cancer","volume":"17","author":"Iams","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"Pt 2","key":"10.1016\/j.ctarc.2026.101275_bib0003","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.semcancer.2022.07.008","article-title":"Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: a bench-to-bedside review","volume":"86","author":"Xiong","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101275_bib0004","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/1759-7714.13846","article-title":"Prognostic factor analysis of patients with small cell lung cancer: real-world data from 988 patients","volume":"12","author":"Ma","year":"2021","journal-title":"Thorac. Cancer"},{"issue":"23","key":"10.1016\/j.ctarc.2026.101275_bib0005","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101275_bib0006","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.annonc.2019.10.021","article-title":"Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I\/III trial","volume":"31","author":"Mansfield","year":"2020","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101275_bib0007","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol."},{"issue":"10212","key":"10.1016\/j.ctarc.2026.101275_bib0008","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101275_bib0009","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line Serplulimab vs Placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA, J. Am. Med. Assoc."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101275_bib0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/jamaoncol.2024.5019","article-title":"Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: the phase 3 EXTENTORCH randomized clinical trial","volume":"11","author":"Cheng","year":"2025","journal-title":"JAMa Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101275_bib0011","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","article-title":"Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial","volume":"30","author":"Cheng","year":"2024","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101275_bib0012","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial","volume":"19","author":"Cheng","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"14","key":"10.1016\/j.ctarc.2026.101275_bib0013","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101275_bib0014","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ctarc.2026.101275_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1281888","article-title":"Efficacy and safety of definitive chemoradiotherapy with or without induction immune checkpoint inhibitors in patients with stage III non-small cell lung cancer","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101275_bib0016","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3390\/cells8070678","article-title":"ARID1A Mutations are associated with increased immune activity in gastrointestinal cancer","volume":"8","author":"Li","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101275_bib0017","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3724\/abbs.2021011","article-title":"PARP-1 inhibitors enhance the chemosensitivity of leukemia cells by attenuating NF-\u043ab pathway activity and DNA damage response induced by Idarubicin","volume":"54","author":"Ke","year":"2022","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101275_bib0018","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1878-0261.12032","article-title":"Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells","volume":"11","author":"Yang","year":"2017","journal-title":"Mol. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101275_bib0019","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3892\/mco.2024.2718","article-title":"Neutrophil\u2011to\u2011lymphocyte ratio reflects lung injury in thoracic radiotherapy and immune checkpoint inhibitors combination therapy with different sequences","volume":"20","author":"Tong","year":"2024","journal-title":"Mol. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101275_bib0020","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2026.101275_bib0021","article-title":"Case report: a golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib","volume":"15","author":"Fu","year":"2024","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101275_bib0022","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41385-021-00467-7","article-title":"Human mucosal tissue-resident memory T cells in health and disease","volume":"15","author":"Lange","year":"2022","journal-title":"Mucosal. Immunol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101275_bib0023","doi-asserted-by":"crossref","first-page":"907","DOI":"10.4049\/jimmunol.2300049","article-title":"Memory T cells in the immunoprevention of cancer: a switch from therapeutic to prophylactic approaches","volume":"211","author":"Mittra","year":"2023","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101275_bib0024","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.molmed.2020.10.004","article-title":"PD-L1 and B7-1 cis-interaction: new mechanisms in immune checkpoints and immunotherapies","volume":"27","author":"Nishimura","year":"2021","journal-title":"Trends. Mol. Med."},{"key":"10.1016\/j.ctarc.2026.101275_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1163971","article-title":"Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: a systematic review and network meta-analysis of phase 3 trials","volume":"14","author":"Hou","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101275_bib0026","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.5306\/wjco.v12.i12.1182","article-title":"Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer","volume":"12","author":"Sereno","year":"2021","journal-title":"World J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101275_bib0027","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157339406777934717","article-title":"Cancer therapy-induced residual bone marrow injury-mechanisms of induction and implication for therapy","volume":"2","author":"Wang","year":"2006","journal-title":"Curr. Cancer Ther. Rev."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:20Z","timestamp":1790913680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":27,"alternative-id":["S2468294226001863"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101275","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy and safety of an overall strategy of immunotherapy combined with chemoradiotherapy for limited-stage small cell lung cancer (including induction \u00b1 consolidation \u00b1 second-line immunotherapy): A propensity score matching study based on real-world data","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101275"}}